Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures~2. Newly diagnosed type 2 diabetic patients or type 2 diabetic patients on hypoglycemic agents between the age of 30 to 70~3. Non-ST elevation Acute coronary syndrome with successful coronary stent implantation (with TIMI flow grade 3 after the procedure)~Exclusion Criteria:~1. Hypersensitivity to ticagrelor, prasugrel or any of the excipients~2. No prior use of either ticagrelor or prasugrel within a month prior to randomization.~3. History of intracranial bleeding at any time~4. Active pathologic bleeding~5. Hemoglobin A1c \>9%~6. Type 1 diabetes~7. Decreased serum platelet level (\< 100,000/uL)~8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin~9. Gastrointestinal bleed within the past 6 months, or major surgery within 30 days~10. Renal failure requiring dialysis or anticipated need for dialysis during the course of the study~11. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study~12. Involvement in the planning and/or conduct of the study~13. Left ventricular ejection fraction \< 40%~14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase \> twice the upper limit)~15. Gastrointestinal disorder such as Crohn's disease~16. Alcohol abuse~17. Steroid or hormone replacement therapy~18. Serum creatinine \> 2.0 mg/dL.~19. Prior history of CVA or stroke~20. Body weight \< 60 kg~21. Life expectancy less than a year~22. Known pregnancy, breast-feeding, or intend to become pregnant during the study period

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: ACTIVE_COMPARATOR): 180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
- Prasugrel (Type: ACTIVE_COMPARATOR): 60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor

Based on this trial design, predict the completion outcome and termination type (if applicable).